Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1976 1
1981 3
1983 4
1984 5
1985 14
1986 18
1987 15
1988 5
1989 13
1990 8
1991 7
1992 10
1993 6
1994 13
1995 15
1996 12
1997 10
1998 10
1999 14
2000 13
2001 21
2002 16
2003 12
2004 24
2005 23
2006 24
2007 27
2008 12
2009 10
2010 12
2011 15
2012 13
2013 13
2014 12
2015 11
2016 10
2017 12
2018 14
2019 11
2020 17
2021 8
2022 7
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

502 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for gershenson d[au]
Your search for Hershenzon D[au] retrieved no results
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. Among authors: gershenson dm. J Natl Compr Canc Netw. 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. J Natl Compr Canc Netw. 2021. PMID: 33545690
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. Armstrong DK, et al. Among authors: gershenson dm. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. J Natl Compr Canc Netw. 2022. PMID: 36075393
Management of borderline ovarian tumours.
Gershenson DM. Gershenson DM. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:49-59. doi: 10.1016/j.bpobgyn.2016.09.012. Epub 2016 Oct 3. Best Pract Res Clin Obstet Gynaecol. 2017. PMID: 27780698 Review.
Low-grade serous ovarian cancer: State of the science.
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Slomovitz B, et al. Among authors: gershenson dm. Gynecol Oncol. 2020 Mar;156(3):715-725. doi: 10.1016/j.ygyno.2019.12.033. Epub 2020 Jan 20. Gynecol Oncol. 2020. PMID: 31969252 Review.
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Gershenson DM, et al. Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9. Lancet. 2022. PMID: 35123694 Free PMC article. Clinical Trial.
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Thaker PH, et al. Among authors: gershenson dm. Nat Med. 2006 Aug;12(8):939-44. doi: 10.1038/nm1447. Epub 2006 Jul 23. Nat Med. 2006. PMID: 16862152
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL. Slomovitz BM, et al. Among authors: gershenson dm. J Clin Oncol. 2015 Mar 10;33(8):930-6. doi: 10.1200/JCO.2014.58.3401. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624430 Free PMC article. Clinical Trial.
Rare Gynecologic Tumors: Coming of Age.
Gershenson DM, Okamoto A, Ray-Coquard I. Gershenson DM, et al. Gynecol Oncol. 2020 Apr;157(1):1-2. doi: 10.1016/j.ygyno.2020.03.001. Gynecol Oncol. 2020. PMID: 32241340 No abstract available.
Mucinous Ovarian Carcinoma.
Hackshaw A, Gershenson D, Ledermann J. Hackshaw A, et al. Among authors: gershenson d. N Engl J Med. 2019 Jul 4;381(1):e3. doi: 10.1056/NEJMc1905728. N Engl J Med. 2019. PMID: 31269388 No abstract available.
502 results